Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing for CHEK2 in the cancer genetics clinic: ready for prime time?

Clinical genetics - 1 Jul 2010

Narod S A

Abstract excerpt

The 1100delC mutation of the CHEK2 gene was found to be a cause of breast cancer in 2002. The lifetime risk of breast cancer among women with a mutation and with a family history of breast cancer is approximately 25%. These women are good candidates for screening with MRI and for chemoprevention with tamoxifen. It is reasonable to test for this single mutation when women undergo testing for BRCA1 and BRCA2.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Checkpoint Kinase 2
Share to Chemoprevention

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Magnetic Resonance Imaging

Share to Mass Screening

Share to Protein Serine-Threonine Kinases

Share to Tamoxifen

Source

Identifiers

PMID: 20597917
DOI: 10.1111/j.1399-0004.2010.01402.x

Genes

CHEK2
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing for CHEK2 in the cancer genetics clinic: ready for prime time?PMID 20597917Read ↗

Is CHEK2 a moderate-risk breast cancer gene or the younger sister of Li-Fraumeni?Semantic proximity Read ↗

Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.Semantic proximity Read ↗

The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations.Semantic proximity Read ↗

Mutations of the CHEK2 gene in patients with cancer and their presence in the Latin American populationSemantic proximity Read ↗

Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.Semantic proximity Read ↗

Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation.Semantic proximity Read ↗

Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers.Semantic proximity Read ↗

Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants.Semantic proximity Read ↗

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.Semantic proximity Read ↗

The CHEK2 gene and inherited breast cancer susceptibility.Semantic proximity Read ↗

Analysis of familial male breast cancer for germline mutations in CHEK2.Semantic proximity Read ↗

[CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.